SIA
NBIX icon

Sit Investment Associates’s Neurocrine Biosciences NBIX Stock Holding History

Sit Investment Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,700
Closed -$1.85M – 524
2022
Q1 		$1.85M Hold
19,700
– – 0.05% 302
2021
Q4 		$1.68M Hold
19,700
– – 0.04% 328
2021
Q3 		$1.89M Hold
19,700
– – 0.05% 303
2021
Q2 		$1.92M Hold
19,700
– – 0.05% 301
2021
Q1 		$1.92M Buy
+19,700
New +$2.07M 0.05% 306
2019
Q1 		– Sell
-13,750
Closed -$982K – 547
2018
Q4 		$982K Buy
13,750
+3,800
+38% +$364K 0.03% 331
2018
Q3 		$1.22M Sell
9,950
-950
-9% -$108K 0.03% 314
2018
Q2 		$1.07M Buy
+10,900
New +$976K 0.03% 350

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Sit Investment Associates's NBIX Position: Q2 2022 in Review

Sit Investment Associates sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 19,700 shares — an estimated $1.85M sold.

Sit Investment Associates first reported a position in NBIX in Q2 2018 and held it in 8 quarters. The position peaked at $1.92M in Q2 2021. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Sit Investment Associates reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
  • Sit Investment Associates sold 19,700 Neurocrine Biosciences shares in Q2 2022, an estimated $1.85M.
  • Sit Investment Associates first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 8 quarters.
  • Sit Investment Associates's Neurocrine Biosciences position peaked at $1.92M in Q2 2021.
  • 437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Sit Investment Associates's 13F filing for Q2 2022, filed 11 Aug 2022.